Profile data is unavailable for this security.
About the company
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
- Revenue in USD (TTM)0.00
- Net income in USD-39.03m
- Incorporated2007
- Employees91.00
- LocationNeurogene Inc535 W 24Th Street, 5Th FloorNEW YORK 10011United StatesUSA
- Phone+1 (206) 732-2133
- Fax+1 (302) 655-5049
- Websitehttps://www.neurogene.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nkarta Inc | 0.00 | -116.20m | 533.44m | 150.00 | -- | 1.13 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Contineum Therapeutics Inc | 50.00m | 19.13m | 541.73m | 31.00 | 27.67 | -- | 27.99 | 10.83 | 0.7611 | 0.7611 | 1.99 | 4.66 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 38.25 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 552.04m | 100.00 | -- | 5.56 | -- | 6.53 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Lenz Therapeutics Inc | 0.00 | -117.37m | 556.91m | 6.00 | -- | 2.81 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
OmniAB Inc | 21.05m | -63.48m | 561.03m | 106.00 | -- | 1.86 | -- | 26.66 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Alector Inc | 96.41m | -120.61m | 561.92m | 244.00 | -- | 3.14 | -- | 5.83 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Neurogene Inc | 0.00 | -39.03m | 575.55m | 91.00 | -- | 3.34 | -- | -- | -4.58 | -4.58 | 0.00 | 13.28 | 0.00 | -- | -- | 0.00 | -26.57 | -32.70 | -28.41 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
PepGen Inc | 0.00 | -80.33m | 578.97m | 64.00 | -- | 3.23 | -- | -- | -3.25 | -3.25 | 0.00 | 5.53 | 0.00 | -- | -- | 0.00 | -39.37 | -- | -42.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 603.01m | 57.00 | -- | 3.05 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
Annexon Inc | 0.00 | -120.74m | 607.45m | 70.00 | -- | 2.02 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
iTeos Therapeutics Inc | 0.00 | -135.31m | 614.45m | 157.00 | -- | 1.13 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
GH Research PLC | 0.00 | -35.59m | 614.45m | 49.00 | -- | 2.81 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
Grail Inc | 100.18m | -1.49bn | 615.39m | 1.36k | -- | 0.1407 | -- | 6.14 | -56.16 | -56.16 | 3.77 | 140.84 | -- | -- | -- | 74,763.43 | -- | -47.45 | -- | -48.55 | 41.91 | -- | -1,488.21 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 1.27m | 9.79% |
Great Point Partners LLCas of 31 Mar 2024 | 1.00m | 7.74% |
Redmile Group LLCas of 31 Mar 2024 | 935.25k | 7.21% |
Janus Henderson Investors US LLCas of 31 Mar 2024 | 813.35k | 6.27% |
RTW Investments LPas of 31 Mar 2024 | 769.12k | 5.93% |
BlackRock Advisors LLCas of 31 Mar 2024 | 719.54k | 5.54% |
Cormorant Asset Management LPas of 31 Mar 2024 | 538.71k | 4.15% |
Casdin Capital LLCas of 31 Mar 2024 | 524.62k | 4.04% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 511.40k | 3.94% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 503.42k | 3.88% |